Immortalized Mast Cell Progenitors for Allergy Assays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current allergy diagnostic tools are complex, laborious, and lack a convenient, safe, and standardized method to predict functional reactivity against allergens, with existing methods being inefficient and unreliable, particularly in assessing patient response to allergen-specific immunotherapy.
Innovation Solution
Development of non-human conditionally immortalized mast cell progenitors engineered to express a heterologous high-affinity IgE receptor alpha subunit (FcεRIα) using an inducible homeobox gene, allowing for the production of mast cells that can be used in assays to determine allergy severity and treatment effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fresh whole blood samples are used for basophil activation testing, then functional information about allergic status can be obtained, but the biological material becomes unstable and cannot be stored for later analysis
Solution Approach 1:
The patent applies preliminary action by preparing and freezing mast cell progenitors before they are needed for testing. The progenitors are engineered to express human FcεRIα and can be stored at -70°C or in liquid nitrogen, allowing them to be thawed and used later for allergy testing without degradation, thus resolving the instability issue of fresh blood samples
Solution Approach 2:
The patent creates a cellular copy system where non-human mast cell progenitors engineered with human FcεRIα serve as functional copies of human mast cells. These engineered progenitors can be frozen and stored, then thawed to perform the same functional assays as fresh human blood, eliminating the need for immediate analysis of unstable biological material
2Reliability
If primary human blood-derived mast cells are used for allergy testing, then functional reactivity can be assessed, but the generation process becomes laborious and requires extended culturing periods of more than two months
Solution Approach 1:
The patent changes the species parameter by using non-human mast cell progenitors (such as mouse or rat) that are engineered to express human FcεRIα, rather than attempting to culture human mast cells from scratch. This approach dramatically reduces the culturing time required while maintaining functional reactivity assessment capability through the engineered human receptor expression
Solution Approach 2:
The patent introduces an intermediary approach by using engineered non-human mast cell progenitors as mediators between the testing system and the human allergic response. These progenitors express human FcεRIα, allowing them to bind human IgE and respond to human allergens, thus serving as functional intermediaries that eliminate the need for lengthy human cell culture periods
3Reliability
If in vivo allergen challenge tests are performed to assess patient response to immunotherapy, then treatment effectiveness can be determined, but the tests are unpleasant for patients and risk inducing allergic reactions
Solution Approach 1:
The patent replaces the mechanical/invasive in vivo allergen challenge test with an in vitro cellular assay system. Engineered mast cell progenitors are used to assess treatment response through controlled laboratory conditions, eliminating the need for patients to undergo invasive skin prick tests or allergen challenges, thus removing the associated discomfort and reaction risks while maintaining diagnostic reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a reliable and standardized method for allergy testing and monitoring of allergen-specific immunotherapy, enabling precise assessment of patient responses and allergen reactivity, reducing the need for invasive tests and improving diagnostic accuracy.
Implementation Method 1
introducing a nucleic acid molecule comprising an inducible homeobox gene into myeloid progenitor cells, wherein said myeloid progenitor cells are derived from a non-human animal and are engineered to express a heterologous high-affinity IgE receptor alpha subunit (FcεRIα)
Implementation Method 2
contacting the mast cells with the allergen; and detecting activation of the mast cells
Data Source
AI summary
A method for producing non-human conditionally immortalized mast cell progenitors comprises: introducing a nucleic acid molecule comprising an inducible homeobox gene into myeloid progenitor cells, wherein said myeloid progenitor cells are derived from a non-human animal and are engineered to express a heterologous high-affinity IgE receptor alpha subunit (FcεRIα); and selecting for cells which contain the nucleic acid molecule. The non-human conditionally immortalized mast cell progenitors may be cultured to obtain differentiated mast cells. The mast cells find utility in assays for the determination of IgE mediated allergies.